• print
  • mail
  • Home
  • Media
  • In the News

  • Overview
  • Fact Sheets
  • Featured Content
  • Press Releases
  • Social Media
  • Media Contacts
  • In the News
  • Corporate News
  • Biosimilars in the News
  • Enbrel® in the News
  • ESAs in the News
  • Pipeline in the News
  • Prolia® in the News
  • Neulasta® in the News
  • Nplate® in the News
  • Vectibix® in the News
  • XGEVA™ in the News
  • Virtual Press Kits
In the News
 Corporate News
Oct. 25, 2010
Amgen Statement on Puerto Rico Tax Legislation

more >

Biosimilars in the News
May 11, 2012
Amgen Provides Testimony at FDA Stakeholder Hearing on Draft Guidances Relating to the Development of Biosimilar Products
Apr. 16, 2012
Amgen Submits Comments in Response to FDA's Draft Guidance on Biosimilars
Feb. 9, 2012
Amgen Statement on FDA Draft Guidance on Biosimilar Product Development

Background Documents

Learn more about biosimilars

more >

Enbrel® (etanercept) in the News
Apr. 24, 2009
Amgen and Wyeth announce ENBREL Support™ Program
Mar.18, 2009
Amgen Statement on Alzheimer's Case Study
Sept. 4, 2008
Press Release: Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers

Background Documents

Prescribing information for Enbrel®

more >

ESAs in the News
Sep. 01, 2011
Amgen Statement on Proposed Changes to the Quality Incentive Program in Dialysis
Jun. 24, 2011
Amgen Posts Modified ESA Labeling
Jan. 19, 2011
Amgen Presents at MEDCAC Meeting on ESAs in Chronic Kidney Disease

Background Documents

Prescribing information for Aranesp®
Prescribing information for EPOGEN®

more >

Pipeline in the News
May 16, 2012
Amgen at ASCO 2012
Nov. 26, 2010
Amgen Statement on Briefing Materials Prepared for November 30, 2010 Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee Meeting
Oct. 28, 2010
Amgen to Participate in Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee

more >

Prolia® (denosumab) in the News
May 11, 2012
Amgen Modifies U.S. Prescribing Information for Prolia® (denosumab)
Sep. 19, 2011
Press Release: FDA Approves New Indications for Prolia® (denosumab) for the Treatment of Bone Loss in Patients with Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
Sep. 19, 2011
Amgen Modifies U.S. Prescribing Information for Prolia® (denosumab)

Background Documents

Prescribing information for Prolia®

more >

Neulasta® (pegfilgrastim) in the News
June 19, 2009
Amgen Introduces Neulasta FIRST STEP™ Program

Background Documents

Prescribing information for Neulasta®

more >

Nplate® (romiplostim) in the News
Dec. 6, 2011
Amgen and FDA Agree to Modify Nplate® Risk Evaluation and Mitigation Strategy
Jul. 27, 2011
Amgen Modifies U.S. Prescribing Information for Nplate® (romiplostim)

Background Documents

Prescribing information for Nplate®

more >

Vectibix® (panitumumab) in the News

Jan. 12, 2012
Amgen Modifies U.S. Prescribing Information for Vectibix® (panitumumab)
Feb. 4, 2011
Amgen Statement on Briefing Materials Prepared for February 8, 2011 Oncologic Drugs Advisory Committee Meeting
Jan. 6, 2011
Amgen to Participate in the February 8, 2011 Oncologic Drugs Advisory Committee (ODAC) Meeting on the Status of Accelerated Approvals

Background Documents

Prescribing information for Vectibix®

more >

XGEVA™ (denosumab) in the News
May 2, 2012
Amgen Modifies U.S. Prescribing Information for XGEVA® (denosumab)
Apr. 27, 2012
Amgen Modifies U.S. Prescribing Information for XGEVA® (denosumab)
Feb. 6, 2012
Amgen Statement on Briefing Materials for Oncologic Drugs Advisory Committee Meeting on February 8, 2012

Background Documents

Prescribing Information for XGEVA® (denosumab) (US)

 


  • Related Links
  • Products
  • Pipeline
  • Corporate Citizenship
  • Locations
footer